Assessment cycle 2023 Q1 — page 7
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low20 Apr 2024 -
Observational, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low07 Aug 2023 -
Observational, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low18 Sep 2023 -
Randomised crossover, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low07 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low05 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low08 Jan 2024 -
Single-arm open-label, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over open-label extension of the parent trial. The Institute holds no reported…
Very low18 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low21 Oct 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low05 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low20 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low29 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low08 Jun 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 May 2024 -
Randomised crossover, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Jan 2024 -
Randomised crossover, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low22 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low13 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Mar 2024 -
Observational, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 May 2024 -
Randomised crossover, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low24 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low04 Apr 2024 -
Single-arm open-label, phase 1 study of Ipamorelin in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low22 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported…
Very low23 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Jan 2024 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low16 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low02 Sep 2023 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Mar 2024 -
Single-arm open-label, phase 2 study of Thymosin beta-4 in wound healing over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low23 Jun 2023
page 7 of 13